348 related articles for article (PubMed ID: 11281386)
21. The role of accessory cells in allogeneic peripheral blood stem cell transplantation.
Tanaka J; Imamura M; Kasai M; Asaka M; Torok-Storb B
Int J Hematol; 1999 Feb; 69(2):70-4. PubMed ID: 10071453
[TBL] [Abstract][Full Text] [Related]
22. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
23. Regulatory CD4+CD25hi T cells conserve their function and phenotype after granulocyte colony-stimulating factor treatment in human hematopoietic stem cell transplantation.
Noël G; Bruniquel D; DeGuibert S; Birebent B; Grosset JM; Bernard M; Dauriac C; Lamy-de-la-Chapelle T; Semana G; Brinster C
Hum Immunol; 2008 Jun; 69(6):329-37. PubMed ID: 18571003
[TBL] [Abstract][Full Text] [Related]
24. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
[TBL] [Abstract][Full Text] [Related]
25. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
26. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen.
Dey BR; Shaffer J; Yee AJ; McAfee S; Caron M; Power K; Ting DT; Colby C; Preffer F; Ballen K; Attar E; Saidman S; Tarbell N; Sachs D; Sykes M; Spitzer TR
Bone Marrow Transplant; 2007 Jul; 40(1):19-27. PubMed ID: 17468773
[TBL] [Abstract][Full Text] [Related]
27. Phenotype of lymphocyte subsets after autologous peripheral blood stem cell transplantation.
Koehne G; Zeller W; Stockschlaeder M; Zander AR
Bone Marrow Transplant; 1997 Jan; 19(2):149-56. PubMed ID: 9116612
[TBL] [Abstract][Full Text] [Related]
28. Blood versus marrow hematopoietic allogeneic graft.
Robinet E; Lapierre V; Tayebi H; Kuentz M; Blaise D; Tiberghien P
Transfus Apher Sci; 2003 Aug; 29(1):53-9. PubMed ID: 12877895
[TBL] [Abstract][Full Text] [Related]
29. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts.
Theilgaard-Mönch K; Raaschou-Jensen K; Palm H; Schjødt K; Heilmann C; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 2001 Dec; 28(11):1073-82. PubMed ID: 11781619
[TBL] [Abstract][Full Text] [Related]
30. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells.
Russell JA; Bowen T; Brown C; Luider J; Ruether JD; Stewart D; Jorgenson K; Coppes MJ; Turner AR; Larratt L; Chaudhry A; Booth K; Poon MC; Klassen J
Bone Marrow Transplant; 1996 Sep; 18(3):501-5. PubMed ID: 8879609
[TBL] [Abstract][Full Text] [Related]
31. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
32. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
[TBL] [Abstract][Full Text] [Related]
33. Haploidentical peripheral blood and marrow stem cell transplantation in nine cases of primary immunodeficiency.
Lanfranchi A; Verardi R; Tettoni K; Neva A; Mazzolari E; Pennacchio M; Pasic S; Ugazio AG; Albertini A; Porta F
Haematologica; 2000 Nov; 85(11 Suppl):41-6. PubMed ID: 11268323
[TBL] [Abstract][Full Text] [Related]
34. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
[TBL] [Abstract][Full Text] [Related]
35. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor.
Gyger M; Stuart RK; Perreault C
Bone Marrow Transplant; 2000 Jul; 26(1):1-16. PubMed ID: 10918400
[TBL] [Abstract][Full Text] [Related]
36. Immune reconstitution after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host disease.
Abrahamsen IW; Sømme S; Heldal D; Egeland T; Kvale D; Tjønnfjord GE
Haematologica; 2005 Jan; 90(1):86-93. PubMed ID: 15642674
[TBL] [Abstract][Full Text] [Related]
37. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Alessandrino EP; Bernasconi P; Caldera D; Colombo A; Malcovati L; Martinelli G; Bonfichi M; Pagnucco G; Salvaneschi L; Bernasconi C
Bone Marrow Transplant; 1999 Mar; 23(6):607-12. PubMed ID: 10217192
[TBL] [Abstract][Full Text] [Related]
39. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor.
Jun HX; Jun CY; Yu ZX
Haematologica; 2004 Dec; 89(12):1517-24. PubMed ID: 15590404
[TBL] [Abstract][Full Text] [Related]
40. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
